REVIEW PAPER
The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review
Submission date: 2015-07-10
Acceptance date: 2015-07-28
Publication date: 2016-10-25
Cent Eur J Immunol 2016;41(3):302-310
KEYWORDS
ABSTRACT
Inflammatory bowel diseases (IBDs) are chronic, relapsing inflammatory diseases characterized by exacerbations and remissions of the gastrointestinal tract, clinically manifested as Crohn’s disease and ulcerative colitis. The etiology of IBDs is considered to be multi factorial, comprising environmental, immune, microbial and genetic factors. Clinical signs may include abdominal pain, frequent bloody diarrheas, mucorrhea, vomiting, fever, fatigue or weight loss. Changes in the oral cavity often precede intestinal symptoms. Inflammatory bowel disease leads to a significant deterioration of oral health, which indicates that cooperation between the dentist and the gastroenterologist is necessary when considering patients’ welfare. Patients with IBD have an altered immune response, but microorganisms of the oral cavity may also be responsible for its modification.
This review paper discusses the correlation between the immune system and inflammatory bowel disease manifestations in the oral cavity.
This review paper discusses the correlation between the immune system and inflammatory bowel disease manifestations in the oral cavity.
REFERENCES (105)
3.
Dogan B, Scherl E, Bosworth B, et al. (2013): Multidrug resistance is common in Escherichia coli associated with ileal Crohn’s disease. Inflamm Bowel Dis 19: 141-150.
4.
Cho JH, Brant SR (2011): Recent Insights into the Genetics of Inflammatory Bowel Disease. Gastroenterology 140: 1704-1712.
5.
Marks DJ, Rahman FZ, Sewell GW, Segal AW (2010): Crohn’s disease: An immune deficiency state. Clin Rev Allergy Immunol 38: 20-31.
6.
Trikudanathan G, Venkatesh PG, Navaneethan U (2012): Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 72: 2333-2349.
7.
Raza A, Yousaf W, Giannella R, Shata MT (2012): Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol 8: 161-168.
8.
Kappeler A, Mueller C (2000): The role of activated cytotoxic T cells in inflammatory bowel disease. Histol Histopathol 15: 167-172.
9.
Abbas AK, Lichtman AH, Pillai S (2012): Cellular and molecular immunology. 7 ed. Elsevier, Philadelphia; 225-243.
10.
Zdravkovic ND, Jovanovic IP, Radosavljevic GD, et al. (2014): Potential Dual Immunomodulatory Role of VEGF in Ulcerative Colitis and Colorectal Carcinoma. Int J Med Sci 11: 936-947.
11.
Hyun JG, Mayer L (2006): Mechanisms underlying inflammatory bowel disease. Drug Discov Today Dis Mech 3: 457-462.
12.
Shih DQ, Targan SR (2008): Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 126: 1620-1633.
13.
Li MC, He SH (2004): IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 10: 620-625.
14.
Murata Y, Ishiguro Y, Itoh J (1995): The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol 30: 56-60.
15.
Atreya R, Neurath MF (2005): Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 28: 187-195.
16.
Bernardo D, Vallejo-Díez S, Mann ER, et al. (2012): IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate. Eur J Immunol 42: 1337-1353.
17.
Oukka M (2007): Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 66: 87-90.
18.
Romagnani S, Maggi E, Liotta F, et al. (2009): Properties and origin of human Th17 cells. Mol Immunol 47: 3-7.
19.
Louten J, Boniface K, de Waal Malefyt R (2009): Development and function of Th17 cells in health and disease. J Allergy Clin Immunol 123: 1004-1011.
20.
Ghilardi N, Ouyang W (2007): Targeting the development and effector functions of Th17 cells. Semin Immunol 19: 383-393.
21.
Fuss IJ, Heller F, Boirivant M, et al. (2004): Non classical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113: 1490-1497.
22.
Jiang W, Su J, Zhang X, et al. (2014): Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 63: 943-950.
23.
Lohr J, Knoechel B, Caretto D, Abbas AK (2009): Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect 11: 589-593.
24.
Zorzi F, Monteleone I, Sarra M, et al. (2013): Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s Disease. PLoS One 8: e54562.
25.
Ogino T, Nishimura J, Barman S, et al. (2013): Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn’s disease. Gastroenterology 145: 1380-1391.
26.
Xavier RJ, Podolsky DK (2007): Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
27.
Vucelic B i saradnici. (2002): Gastroenterologija i hepatologija. I edicija. Zagreb.
28.
Sarto RB (2006): Mechanisms of Disease: Pathogenesis of Crohn’s Disease and Ulcerative Colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407.
29.
Szczeklik K, Owczarek D, Pytko-Polończyk J (2012): Proinflammatory cytokines in the saliva of patients with active and nonactive Crohn’s disease. Pol Arch Med Wewn 122: 200-208.
30.
Solem CA, Loftus EV, Tremaine WJ, et al. (2005): Correlation of C-reactive protein with clinical, endoscopic, histologic and radiographic activity in inflammatory bowel disease. Inflammatory Bowel Diseases 11: 707-712.
31.
Schreiber S, Heinig T, Thiele HG, Raedler A (1995): Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108: 1434-1444.
32.
Fujino S, Andoh A, Bamba S, et al. (2003): Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
33.
Yen D, Cheung J, Scheerens H, et al. (2006): IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.
34.
Fuss IJ, Heller F, Boirivant M, et al. (2004): Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113: 1490-1497.
37.
Fatahzadeh M (2009): Inflammatory bowel disease. Oral Surg Oral Med Oral Radiol Endod 108: e1-e10.
38.
Greenstein AJ, Janowitz HD, Sachar DB (1976): The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine 55: 401-412.
39.
Scheper HJ, Brand HS (2009): Oral aspects of Crohn’s disease. Int Dent J 52: 163-172.
40.
Galbraith SS, Drolet BA, Kugathasan S, et al. (2005): Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 116: 439-445.
41.
Dupuy A, Cosnes J, Revuz J, et al. (1999): Oral Crohn’s disease: clinical characteristics and long term follow up of 9 cases. Arch Dermatol 135: 439-442.
42.
Graham DB, Jager DL, Borum ML (2006): Metastatic Crohn’s disease to the face. Dig Dis Sci 51: 2062-2063.
43.
Storwick GS, Prihoda MB, Fulton RJ, Wood WS (1994): Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Derm 31: 336-341.
44.
Chan SW, Scully C, Prime SS, Eveson J (1991): Pyostomatitis vegetans: oral manifestation of ulcerous colitis. Oral Surg Oral Med Oral Pathol 72: 689-692.
45.
Hansen LS, Silverman S Jr, Daniels TE (1983): The differential diagnosis of pyostomatitis vegetans and its relation to bowel disease. Oral Surg Oral Med Oral Pathol 55: 363-373.
46.
Jarrett P, Duffill M, Oakley A, Smith A (1997): Pellagra, azathiorpine and inflammatory bowel disease. Clin Exp Derm 22: 44-45.
47.
Oliva MM, Lake AM (1996): Nutritional considerations and management of the child with inflammatory bowel disesase. Nutrition 12: 151-158.
48.
Franch AM, Soriano YJ, Sarrion Perez MG (2010): Dental management of patients with inflammatory bowel disease. J Clin Exp Dent 2: e191-5.
49.
Szczeklik K, Owczarek D, Pytko-Polończyk J, et al. (2012): Proinflammatory cytokines in the saliva of patients with active and nonactive Crohn’s disease. Pol Arch Med Wewn 122: 200-208.
50.
Aleksandra Nielsen A, Niderby Nielsen J, Schmedes A, et al. (2005): Saliva interleukin-6 in patients with inflammatory bowel disease. Scand J Gastroenterol 40: 1444-1448.
51.
Zhang Y, Lin M, Zhang S, et al. (2008): NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 41: 144-149.
52.
Rhodus NL, Ho V, Miller CS, et al. (2005): NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 29: 42-45.
53.
Rezaie A, Khalaj S, Shabihkhani M, et al. (2006): Study on the Correlations among Disease Acttivity Index and Salivary Transforming Growth Factor-1 and Nitric Oxide in Ulcerative Colitis Patients. Ann N Y Acad Sci 4: 17-21.
54.
Grossner-Schreiber B, Fetter T, Hedderich J, et al. (2006): Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case control study. J Clin Periodontol 33: 478-484.
55.
Brito F, de Barros FC, Zaltman C, et al. (2008): Prevalence of periodontitis and DMFT index in patients with Crohn’s disease and ulcerative colitis. J Clin Periodontol 35: 555-560.
56.
Habashneh RA, Khader YS, Alhumouz MK (2012): The association between inflammatory bowel disease and periodontitis among Jordanians: a case-control study. J Periodontal Res 47: 293-298.
57.
Sundh B, Emilson CG (1989): Salivary and microbial conditions and dental health in patients with Crohn’s disease: a 3 year study. Oral Surg Oral Med Oral Pathol 67: 286-290.
58.
Szymanska S, Lordal M, Rathnayake N, et al. (2014): Dental caries, prevalence and risk factors in patients with Crohn’s disease. PLoS One 9: e91059.
59.
Singhal S, Dian D, Keshavarzian A, et al. (2011): The role of oral hygiene in inflammatory bowel disease. Dig Dis Sci 56: 170-175.
60.
Stein JM, Lammert F, Zimmer V, et al. (2010): Clinical Periodontal and Microbiologic Parameters in Patients With Crohn’s Disease With Consideration of the CARD15 Genotype. J Periodontol 81: 535-545.
61.
Oz HS, Chen T, Etherhole JL (2010): A model for chronic mucosal inflammation in IBD and periodontitis. Dig Dis Sci 55: 2194-2202.
62.
Indriolo A, Greco S, Ravelli P, Fagiuoli S (2011): What can we learn about biofilm/host interactions from the study of inflammatory bowel disease. J Clin Periodontol 38 (Suppl 11): 36-43.
63.
Garlet GP, Matrins WJr, Fonseca BA, et al. (2004): Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. J Clin Periodontol 31: 671-679.
64.
Pizarro TT, Cominelli F (2007): Cytokine therapy for Crohn’s disease. Advances in translational research Ann Rev Med 58: 433-444.
65.
Waddington RJ, Moseley R, Embery G (2000): Periodontal Disease Mechanisms: Reactive oxygen species: a potential role in the pathogenesis of periodontal diseases. Oral Dis 6: 138-151.
66.
Figueredo CM, Brito F, Barros FC, et al. (2011): Expression of cytokines in the gingival crevicular fluid and serum from patients with inflammatory bowel disease and untreated chronic periodontitis. J Periodontal Res 46: 141-146.
67.
Salvi GE, Brown CE, Fujihashi K, et al. Inflammatory mediators of the terminal dentition in adult and early onset periodontitis. J Periodont Res 1998; 33: 212-225.
68.
Schutz T, Drude C, Paulisch E, et al. (2003): Sugar intake, taste changes and dental health in Crohn’s disease. Dig Dis 21: 252-257.
69.
Jarnerot G, Jarnmark I, Nilsson K (1983): Consumption of refined sugars by patients with Crohn’s disease, ulcerative colitis or irritable bowel syndrome. Scand J Gastroent 18: 999-1002.
70.
Marlow GJ, van Gent D, Ferguson LR (2013): Why interleukin-10 supplementation does not work in Crohn’s disease patients. World J Gastroenterol 19: 3931-3941.
71.
Sundh B, Hulden L (1982): Oral status in patients with Crohn’s disease. Acta Chi Scand 148: 531-534.
72.
Han YW, Wang X (2013): Mobile Microbiome: Oral Bacteria in Extra-oral Infections and Inflammation. Dent Res 92: 485-491.
73.
Lockhart PB, Brennan MT, Sasser HC, et al. (2008): Bacteriemia associated with toothbrushing and dental extraction. Circulation 117: 3118-3125.
74.
Naka S, Nomura R, Takashima Y, et al. (2014): A specific Streptococcus mutans strain aggravates non-alcoholic fatty liver disease. Oral Dis 20: 700-706.
75.
Kojimra A, Nakano K, Wada K, et al. (2012): Infection of specific strains of Streptococcus mutans, oral bacteria, confers a risk of ulcerative colitis. Nature Sci Reports 2: doi 10.1038/srep00332.
76.
Strauss J, Kaplan GG, Beck PL, et al. (2011): Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Infl Bow Dis 17: 1971-1978.
77.
Ismail Y, Mahendran V, Ocavia S, et al. (2012): Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from the patients with inflammatory bowel disease. PLoS One 7: e38217.
78.
Nakano K, Nomura R, Hemoto H, et al. (2007): Detection of novel serotype k Streptococcus mutans in infective endocarditis patients. J Med Microbiol 56: 1413-1415.
79.
Nakano K, Nomura R, Nakagawa I, et al. (2004): Demonstration of Streptococcus mutans with a cell wall polysaccharide specific to a new serotype, k, in the human oral cavity. J Clin Microbiol 42: 198-202.
80.
Schreiber S, Fedorak RN, Nielsen OH, et al. (2000): Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology 119: 1461-1472.
81.
Bianchi ML (2010): Inflammatory bowel diseases, celiac disease and bone. Arch Biochem Biophys 503: 54-65.
82.
Harris L, Senagore P, Young VB, McCabe IR (2009): Inflammaoty bowel disease causes reversible supression of osteoblast and chondrocyte function in mice. Am J Phys Gast Liver Phys 296: G1020-G1029.
83.
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D (2007): Impact of local and systemic factors on the incidence of oral implant failures up to abutment connection. J Clin Periodont 34: 610-617.
84.
Alsaadi G, Quirynen M, Michiles K, et al. (2008): Impact of local and systemic factors on the incidence of oral implant failures up to abutment connection with modified surface oral implants. J Clin Periodont 35: 51-57.
85.
Kuchler U, Luvizuto ER, Munoz F, et al. (2013): Bone healing around titanium impalnts in two rat colitis models. Clin Oral Imp Res 24: 224-229.
86.
Thurston RD, Larmonier CB, Majewski PM (2010): Tumor necrosis factor and interferon down regulate Klotho in mice with colitis. Gastroenterology 138: 1384-1394.
87.
Rowland M, Fleming P, Bourke B (2010): Looking in the mouth for Crohn’s disease. Inflamm Bowel Dis 16: 332-337.
88.
Bhavsar M, Amiji M (2008): Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 15: 1200-1209.
89.
Sales-Campos H, Basso PJ, Alves VB, et al. (2014): Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res 48: 96-107.
90.
D’Haens GR, Sartor RB, Silverberg MS, et al. (2014): Future directions in inflammatory bowel disease management. J Crohns Colitis 8: 726-734.
91.
Armuzzi A, Lionetti P, Blandizzi C, et al. (2014): Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 27: 11-32.
92.
Keane J, Gershon S, Wise RP, et al. (2001): Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
93.
Hueber W, Sands BE, Lewitzky S, et al. (2012): Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61: 1693-1700.
94.
Perrier C, Rutgeerts P (2011): Cytokine blockade in inflammatory bowel diseases. Immunotherapy 3: 1341-1352.
95.
Van Deventer SJ, Elson CO, Fedorak RN (1997): Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 113: 383-389.
96.
Colombel JF, Rutgeerts P, Malchow H, et al. (2001): Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 49: 42-46.
97.
Fedorak RN, Gangl A, Elson CO, et al. (2000): Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology 119: 1473-1482.
98.
Herfarth H, Schölmerich J (2002): IL-10 therapy in Crohn’s disease: at the crossroads. Treatment of Crohn’s disease with the anti-inflammatory cytokine interleukin 10. Gut 50: 146-147.
99.
Rachmawati H, Beljaars L, Reker-Smit C, et al. (2004): Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm Res 21: 2072-2078.
100.
Barbara G, Xing Z, Hogaboam CM, et al. (2000): Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 46: 344-349.
101.
Del Carmen S, Zurita-Turk M, Alvarenga Lima F, et al. (2013): A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. Eur J Inflamm 11: 641-645.
102.
Del Carmen S, Martín Rosique R, Saraiva T, et al. (2014): Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model. J Clin Gastroenterol 48 Suppl 1: S12-17.
103.
Vavricka SR, Manser CN, Hediger S, et al. (2013): Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 19: 2768-2777.
104.
Siegel MA, Jacobson JJ (1999): Inflammatory bowel disease and the oral cavity. Oral Surg Oral Med Oral Pathol Endod 87: 12-14.
105.
Sartor RB (2008): Microbial influences in inflammatory bowel diseases. Gastroenterol 134: 577-594.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
